Applied Genetic (NASDAQ: AGTC)
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-09-22 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.430 | -0.330 | 0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Applied Genetic (NASDAQ: AGTC) through any online brokerage.
Other companies in Applied Genetic’s space includes: Virios Therapeutics (NASDAQ:VIRI), Acurx Pharmaceuticals (NASDAQ:ACXP), Synaptogenix (NASDAQ:SNPX), Celyad Oncology (NASDAQ:CYAD) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for Applied Genetic (NASDAQ: AGTC) was reported by Chardan Capital on Wednesday, May 18, 2022. The analyst firm set a price target for 5.00 expecting AGTC to rise to within 12 months (a possible 540.94% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Applied Genetic (NASDAQ: AGTC) is $0.7801 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Applied Genetic.
Applied Genetic’s Q4 earnings are confirmed for Thursday, September 22, 2022.
There is no upcoming split for Applied Genetic.
Applied Genetic is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.